keyword
MENU ▼
Read by QxMD icon Read
search

Cancer research funding

keyword
https://www.readbyqxmd.com/read/29782309/in-memoriam-assistant-professor-kre%C3%A5-imir-kostovi%C3%A4-md-phd-16-october-1969-15-october-2017
#1
Branka Marinović
On a Sunday afternoon almost six months ago, we were deeply moved by the news that our Krešimir is no longer with us. The sad news spread from Sarajevo with the speed only most horrible and saddest news can achieve. And everybody who was reached by these news wondered whether it was possible and whether it was true. Because our professor Kostović left us a day before his 48th birthday. Krešimir Kostović was born on the 16th October 1969 in Zagreb, where he completed primary and secondary education. He enrolled at the University of Zagreb School of Medicine in 1988, and got his medical degree in 1995...
April 2018: Acta Dermatovenerologica Croatica: ADC
https://www.readbyqxmd.com/read/29770759/milk-and-risk-of-colorectal-colon-and-rectal-cancer-in-the-norwegian-women-and-cancer-nowac-cohort-study
#2
Toril Bakken, Tonje Braaten, Anja Olsen, Anette Hjartåker, Eiliv Lund, Guri Skeie
According to World Cancer Research Fund International/American Institute for Cancer Research, it is 'probable' that dairy products decrease the risk of colorectal cancer (CRC). However, meta-analyses restricted to women have not shown associations between milk intake and risk of CRC. The aim of this study was to examine the association between milk intake and risk of CRC, colon cancer and rectal cancer among women. Data from 81 675 participants in the Norwegian Women and Cancer Cohort Study were included, and multivariable Cox proportional hazard regression models were used to investigate milk intake using two different analytical approaches: one that included repeated measurements and one that included baseline measurements only (872 and 1084 CRC cases, respectively)...
June 2018: British Journal of Nutrition
https://www.readbyqxmd.com/read/29753700/spectrum-and-prevalence-of-genetic-predisposition-in-medulloblastoma-a-retrospective-genetic-study-and-prospective-validation-in-a-clinical-trial-cohort
#3
Sebastian M Waszak, Paul A Northcott, Ivo Buchhalter, Giles W Robinson, Christian Sutter, Susanne Groebner, Kerstin B Grund, Laurence Brugières, David T W Jones, Kristian W Pajtler, A Sorana Morrissy, Marcel Kool, Dominik Sturm, Lukas Chavez, Aurelie Ernst, Sebastian Brabetz, Michael Hain, Thomas Zichner, Maia Segura-Wang, Joachim Weischenfeldt, Tobias Rausch, Balca R Mardin, Xin Zhou, Cristina Baciu, Christian Lawerenz, Jennifer A Chan, Pascale Varlet, Lea Guerrini-Rousseau, Daniel W Fults, Wiesława Grajkowska, Peter Hauser, Nada Jabado, Young-Shin Ra, Karel Zitterbart, Suyash S Shringarpure, Francisco M De La Vega, Carlos D Bustamante, Ho-Keung Ng, Arie Perry, Tobey J MacDonald, Pablo Hernáiz Driever, Anne E Bendel, Daniel C Bowers, Geoffrey McCowage, Murali M Chintagumpala, Richard Cohn, Timothy Hassall, Gudrun Fleischhack, Tone Eggen, Finn Wesenberg, Maria Feychting, Birgitta Lannering, Joachim Schüz, Christoffer Johansen, Tina V Andersen, Martin Röösli, Claudia E Kuehni, Michael Grotzer, Kristina Kjaerheim, Camelia M Monoranu, Tenley C Archer, Elizabeth Duke, Scott L Pomeroy, Redmond Shelagh, Stephan Frank, David Sumerauer, Wolfram Scheurlen, Marina V Ryzhova, Till Milde, Christian P Kratz, David Samuel, Jinghui Zhang, David A Solomon, Marco Marra, Roland Eils, Claus R Bartram, Katja von Hoff, Stefan Rutkowski, Vijay Ramaswamy, Richard J Gilbertson, Andrey Korshunov, Michael D Taylor, Peter Lichter, David Malkin, Amar Gajjar, Jan O Korbel, Stefan M Pfister
BACKGROUND: Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines. METHODS: In this international, multicentre study, we analysed patients with medulloblastoma from retrospective cohorts (International Cancer Genome Consortium [ICGC] PedBrain, Medulloblastoma Advanced Genomics International Consortium [MAGIC], and the CEFALO series) and from prospective cohorts from four clinical studies (SJMB03, SJMB12, SJYC07, and I-HIT-MED)...
May 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29749848/institutional-interventions-that-remove-barriers-to-recruit-and-retain-diverse-biomedical-phd-students
#4
Marenda A Wilson, Anthony DePass, Andrew J Bean
The faculty and student populations in academia are not representative of the diversity in the U.S. POPULATION: Thus, research institutions and funding agencies invest significant funds and effort into recruitment and retention programs that focus on increasing the flow of historically underrepresented minorities (URMs) into the science, technology, engineering, and mathematics (STEM) pipeline. Here, we outline challenges, interventions, and assessments by the University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS) that increased the diversity of the student body independently of grade point averages and Graduate Record Examination scores...
June 2018: CBE Life Sciences Education
https://www.readbyqxmd.com/read/29743088/measuring-research-impact-a-large-cancer-research-funding-programme-in-australia
#5
Jacqueline A Bowden, Nicole Sargent, Steve Wesselingh, Lincoln Size, Claire Donovan, Caroline L Miller
BACKGROUND: Measuring research impact is of critical interest to philanthropic and government funding agencies interested in ensuring that the research they fund is both scientifically excellent and has meaningful impact into health and other outcomes. The Beat Cancer Project (BCP) is a AUD $34 m cancer research funding scheme that commenced in 2011. It was initiated by an Australian charity (Cancer Council SA), and supported by the South Australian Government and the state's major universities...
May 9, 2018: Health Research Policy and Systems
https://www.readbyqxmd.com/read/29739753/health-related-quality-of-life-in-adults-with-relapsed-refractory-acute-lymphoblastic-leukemia-treated-with-blinatumomab
#6
Max S Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Anthony Stein, Janet Franklin, Qui Tran, Ze Cong, Andre C Schuh
In the phase 3 TOWER study, blinatumomab significantly improved overall survival in adults with relapsed or refractory (R/R) Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) relative to standard-of-care chemotherapy. A secondary objective of this study was to assess the impact of blinatumomab on health-related quality of life (HRQL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). This analysis included the 342 of 405 randomized patients for whom baseline and ≥1 post-baseline result were available in any EORTC multi-item scale or single-item measure...
May 8, 2018: Blood
https://www.readbyqxmd.com/read/29739463/trade-offs-fairness-and-funding-for-cancer-drugs-key-findings-from-a-deliberative-public-engagement-event-in-british-columbia-canada
#7
Colene Bentley, Sarah Costa, Michael M Burgess, Dean Regier, Helen McTaggart-Cowan, Stuart J Peacock
BACKGROUND: Spending on cancer drugs has risen dramatically in recent years compared to other areas of health care, due in part to higher prices associated with newly approved drugs and increased demand for these drugs. Addressing this situation requires making difficult trade-offs between cost, harms, and ability to benefit when using public resources, making it important for policy makers to have input from many people affected by the issue, including citizens. METHODS: In September 2014, a deliberative public engagement event was conducted in Vancouver, British Columbia (BC), on the topic of priority setting and costly cancer drugs...
May 8, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29727033/patient-centered-prioritization-of-bladder-cancer-research
#8
Angela B Smith, Stephanie Chisolm, Allison Deal, Alejandra Spangler, Diane Z Quale, Rick Bangs, J Michael Jones, John L Gore
BACKGROUND: Patient-centered research requires the meaningful involvement of patients and caregivers throughout the research process. The objective of this study was to create a process for sustainable engagement for research prioritization within oncology. METHODS: From December 2014 to 2016, a network of engaged patients for research prioritization was created in partnership with the Bladder Cancer Advocacy Network (BCAN): the BCAN Patient Survey Network (PSN)...
May 4, 2018: Cancer
https://www.readbyqxmd.com/read/29726071/a-prospective-randomised-multi-centre-study-of-the-impact-of-ga-68-psma-pet-ct-imaging-for-staging-high-risk-prostate-cancer-prior-to-curative-intent-surgery-or-radiotherapy-propsma-study-clinical-trial-protocol
#9
Michael S Hofman, Declan G Murphy, Scott G Williams, Tatenda Nzenza, Alan Herschtal, Richard De Abreu Lourenco, Dale L Bailey, Ray Budd, Rodney J Hicks, Roslyn J Francis, Nathan Lawrentschuk
INTRODUCTION: Accurate staging of patients with prostate cancer is important for therapeutic decision making. Relapse following surgery or radiotherapy of curative intent is not uncommon and, in part, represents a failure of staging with current diagnostic imaging techniques to detect disease spread. Prostate-specific-membrane-antigen (PSMA) positron emission tomography / computed tomography (PET/CT) is a new whole body scanning technique that enables visualisation of prostate cancer with high contrast...
May 3, 2018: BJU International
https://www.readbyqxmd.com/read/29719427/barriers-to-participation-in-clinical-trials-a-physician-survey
#10
A Mahmud, O Zalay, A Springer, K Arts, E Eisenhauer
Background: Clinical trials are vital for evidence-based cancer care. Oncologist engagement in clinical trials has an effect on patient recruitment, which in turn can affect trial success. Identifying barriers to clinical trial participation might enable interventions that could help to increase physician participation. Methods: To assess factors affecting physician engagement in oncology trials, a national survey was conducted using the online SurveyMonkey tool (SurveyMonkey, San Mateo, CA, U...
April 2018: Current Oncology
https://www.readbyqxmd.com/read/29717896/the-importance-of-food-nutrition-and-physical-activity-in-cancer-prevention-an-interview-with-dr-kate-allen
#11
Kate Allen
Kate Allen speaks to Roshaine Wijayatunga, Managing Commissioning Editor. Dr Kate Allen works as an Executive Director in Science and Public Affairs at World Cancer Research Fund International ( http://wcrf.org ), an NGO and leading authority in the field of cancer prevention through diet, weight and physical activity. Kate is responsible for the organization's scientific, policy and conference programs in the areas of food, nutrition, physical activity and weight management. An important aspect of her role is helping to create collaborative relationships and activities across the WCRF national charities (in Europe, America and Asia) in these areas, as well as maintaining and creating external partnerships...
May 2, 2018: Future Oncology
https://www.readbyqxmd.com/read/29717499/meeting-report-from-the-prostate-cancer-foundation-psma-directed-radionuclide-scientific-working-group
#12
REVIEW
Andrea K Miyahira, Kenneth J Pienta, Michael J Morris, Neil H Bander, Richard P Baum, Wolfgang P Fendler, William Goeckeler, Michael A Gorin, Hartwig Hennekes, Martin G Pomper, Oliver Sartor, Scott T Tagawa, Scott Williams, Howard R Soule
INTRODUCTION: The Prostate Cancer Foundation (PCF) convened a PSMA-Directed Radionuclide Scientific Working Group on November 14, 2017, at Weill Cornell Medicine, New York, NY. METHODS: The meeting was attended by 35 global investigators with expertise in prostate cancer biology, radionuclide therapy, molecular imaging, prostate-specific membrane antigen (PSMA)-targeted agents, drug development, and prostate cancer clinical trials. The goal of this meeting was to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the studies and clinical trials necessary for validating and optimizing the use of these agents...
May 1, 2018: Prostate
https://www.readbyqxmd.com/read/29713045/author-correction-analysis-of-dna-methylation-in-cancer-location-revisited
#13
Alexander Koch, Sophie C Joosten, Zheng Feng, Tim C de Ruijter, Muriel X Draht, Veerle Melotte, Kim M Smits, Jurgen Veeck, James G Herman, Leander Van Neste, Wim Van Criekinge, Tim de Meyer, Manon van Engeland
The originally published article contained an error in the acknowledgements section in which the Universiteitsfonds Limburg/SWOL is incorrectly presented as awarding an SU2C- DCS International Translational Cancer Research Dream Team Grant (Stand Up To Cancer (SU2C)-AACR- DT1415, MEDOCC). This has been corrected in the HTML and PDF versions of the manuscript to reflect that Universiteitsfonds Limburg/SWOL is not the funding body that awarded this grant.
April 30, 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29712689/a-systematic-analysis-of-uk-cancer-research-funding-by-gender-of-primary-investigator
#14
Charlie D Zhou, Michael G Head, Dominic C Marshall, Barnabas J Gilbert, Majd A El-Harasis, Rosalind Raine, Henrietta O'Connor, Rifat Atun, Mahiben Maruthappu
OBJECTIVES: To categorically describe cancer research funding in the UK by gender of primary investigator (PIs). DESIGN: Systematic analysis of all open-access data. METHODS: Data about public and philanthropic cancer research funding awarded to UK institutions between 2000 and 2013 were obtained from several sources. Fold differences were used to compare total investment, award number, mean and median award value between male and female PIs...
April 30, 2018: BMJ Open
https://www.readbyqxmd.com/read/29709558/bursectomy-versus-omentectomy-alone-for-resectable-gastric-cancer-jcog1001-a-phase-3-open-label-randomised-controlled-trial
#15
Yukinori Kurokawa, Yuichiro Doki, Junki Mizusawa, Masanori Terashima, Hitoshi Katai, Takaki Yoshikawa, Yutaka Kimura, Shuji Takiguchi, Yasunori Nishida, Norimasa Fukushima, Yoshiaki Iwasaki, Masahide Kaji, Motohiro Hirao, Hiroshi Katayama, Mitsuru Sasako
BACKGROUND: The role of bursectomy, in which the peritoneal lining covering the pancreas and the anterior plane of the transverse mesocolon are dissected, has long been controversial for preventing peritoneal metastasis. We investigated the survival benefit of bursectomy in patients with resectable gastric cancer. METHODS: This phase 3, open-label, randomised controlled trial was done at 57 hospitals in Japan. Patients aged 20-80 years who had cT3(SS)-cT4a(SE) histologically proven gastric adenocarcinoma with an Eastern Cooperative Oncology Group performance status of 0 or 1 and body-mass index less than 30 kg/m2 and who did not have distant metastasis or bulky lymph nodes were randomly assigned (1:1) during surgery to receive omentectomy alone (non-bursectomy) or bursectomy...
April 27, 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29698329/trends-in-health-disparities-health-inequity-and-social-determinants-of-health-research-a-17-year-analysis-of-ninr-nci-nhlbi-and-nimhd-funding
#16
Shawn M Kneipp, Todd A Schwartz, Denise J Drevdahl, Mary K Canales, Sheila Santacroce, Hudson P Santos, Ruth Anderson
BACKGROUND: The theoretical landscape of health disparities research now emphasizes health inequities and the role that social determinants of health (SDOH) play in creating and perpetuating them. Whether National Institutes of Health (NIH) funding patterns reflect this theoretical shift is unknown. OBJECTIVES: The aim of this study was to examine the National Institute of Nursing Research's (NINR) funding for research focused on health disparities, health inequities, and SDOH, relative to other key NIH institutes...
May 2018: Nursing Research
https://www.readbyqxmd.com/read/29693501/improving-research-in-radiation-oncology-through-interdisciplinary-collaboration
#17
Jay W Burmeister, Monica W Tracey, Sara E Kacin, Michael M Dominello, Michael C Joiner
The contribution of radiation oncology to the future of cancer treatment depends significantly on our continued clinical progress and future research advancements. Such progress relies on multidisciplinary collaboration among radiation oncologists, medical physicists and radiobiologists. Cultivating collaborative educational and research opportunities among these three disciplines and further investing in the infrastructure used to train both clinicians and researchers will therefore help us improve the future of cancer care...
April 25, 2018: Radiation Research
https://www.readbyqxmd.com/read/29692980/leveraging-national-cancer-institute-programmatic-collaboration-for-uterine-cervix-cancer-patient-accrual-in-puerto-rico
#18
Charles A Kunos, Holly A Massett, Annette Galassi, Joan L Walker, Marge J Good, Luis Báez Díaz, Worta McCaskill-Stevens
Women in the U.S. Commonwealth of Puerto Rico (PR) have a higher age-adjusted incidence rate for uterine cervix cancer than the U.S. mainland as well as substantial access and economic barriers to cancer care. The National Cancer Institute (NCI) funds a Minority/Underserved NCI Community Oncology Research Program in PR (PRNCORP) as part of a national network of community-based health-care systems to conduct multisite cancer clinical trials in diverse populations. Participation by the PRNCORP in NCI's uterine cervix cancer clinical trials, however, has remained limited...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29688882/withdrawn-disparity-in-public-funding-of-therapies-for-metastatic-castrate-resistant-prostate-cancer-across-canadian-provinces
#19
Dixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, Naveen S Basappa, Kim N Chi, Henry J Conter, Brita Danielson, Sebastien J Hotte, Shawn Malone, Fred Saad, Bobby Shayegan, Laura Park-Wyllie, Robert J Hamilton
Ahead of print article withdrawn by publisher.
April 12, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29684151/a-new-framework-for-patient-engagement-in-cancer-clinical-trials-cooperative-group-studies
#20
Patricia A Deverka, Rick Bangs, Karma Kreizenbeck, Deborah M Delaney, Dawn L Hershman, Charles D Blanke, Scott D Ramsey
For the past two decades, the National Cancer Institute (NCI) has supported the involvement of patient advocates in both internal advisory activities and funded research projects to provide a patient perspective. Implementation of the inclusion of patient advocates has varied considerably, with inconsistent involvement of patient advocates in key phases of research such as concept development. Despite this, there is agreement that patient advocates have improved the patient focus of many cancer research studies...
April 18, 2018: Journal of the National Cancer Institute
keyword
keyword
22557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"